Single User License
INR 136060
Site License
INR 272120
Corporate User License
INR 408180

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Colon Cancer-Pipeline Review, H1 2015

Colon Cancer-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Colon Cancer-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Colon Cancer-Pipeline Review, H1 2015', provides an overview of the Colon Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Colon Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colon Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Colon Cancer

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Colon Cancer and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Colon Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Colon Cancer pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Colon Cancer

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Colon Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

Introduction 7

Colon Cancer Overview 8

Therapeutics Development 9

Colon Cancer-Therapeutics under Development by Companies 11

Colon Cancer-Therapeutics under Investigation by Universities/Institutes 21

Colon Cancer-Pipeline Products Glance 26

Colon Cancer-Products under Development by Companies 29

Colon Cancer-Products under Investigation by Universities/Institutes 39

Colon Cancer-Companies Involved in Therapeutics Development 43

Colon Cancer-Therapeutics Assessment 135

Drug Profiles 152

Colon Cancer-Recent Pipeline Updates 422

Colon Cancer-Dormant Projects 487

Colon Cancer-Discontinued Products 500

Colon Cancer-Product Development Milestones 501

Appendix 508

List of Tables

Number of Products under Development for Colon Cancer, H1 2015 31

Number of Products under Development for Colon Cancer-Comparative Analysis, H1 2015 32

Number of Products under Development by Companies, H1 2015 34

Number of Products under Development by Companies, H1 2015 (Contd..1) 35

Number of Products under Development by Companies, H1 2015 (Contd..2) 36

Number of Products under Development by Companies, H1 2015 (Contd..3) 37

Number of Products under Development by Companies, H1 2015 (Contd..4) 38

Number of Products under Development by Companies, H1 2015 (Contd..5) 39

Number of Products under Development by Companies, H1 2015 (Contd..6) 40

Number of Products under Development by Companies, H1 2015 (Contd..7) 41

Number of Products under Development by Companies, H1 2015 (Contd..8) 42

Number of Products under Investigation by Universities/Institutes, H1 2015 44

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 45

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 46

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..3) 47

Comparative Analysis by Late Stage Development, H1 2015 48

Comparative Analysis by Clinical Stage Development, H1 2015 49

Comparative Analysis by Early Stage Development, H1 2015 50

Products under Development by Companies, H1 2015 51

Products under Development by Companies, H1 2015 (Contd..1) 52

Products under Development by Companies, H1 2015 (Contd..2) 53

Products under Development by Companies, H1 2015 (Contd..3) 54

Products under Development by Companies, H1 2015 (Contd..4) 55

Products under Development by Companies, H1 2015 (Contd..5) 56

Products under Development by Companies, H1 2015 (Contd..6) 57

Products under Development by Companies, H1 2015 (Contd..7) 58

Products under Development by Companies, H1 2015 (Contd..8) 59

Products under Development by Companies, H1 2015 (Contd..9) 60

Products under Investigation by Universities/Institutes, H1 2015 61

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 62

Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 63

Products under Investigation by Universities/Institutes, H1 2015 (Contd..3) 64

Colon Cancer-Pipeline by Aduro BioTech, Inc., H1 2015 65

Colon Cancer-Pipeline by Advanced Proteome Therapeutics Corporation, H1 2015 66

Colon Cancer-Pipeline by Advenchen Laboratories, LLC, H1 2015 67

Colon Cancer-Pipeline by AGV Discovery, SAS, H1 2015 68

Colon Cancer-Pipeline by AIMM Therapeutics B.V., H1 2015 69

Colon Cancer-Pipeline by Alethia Biotherapeutics Inc., H1 2015 70

Colon Cancer-Pipeline by AlphaVax, Inc., H1 2015 71

Colon Cancer-Pipeline by Ambrx, Inc., H1 2015 72

Colon Cancer-Pipeline by Anavex Life Sciences Corp., H1 2015 73

Colon Cancer-Pipeline by AndroScience Corporation, H1 2015 74

Colon Cancer-Pipeline by ANP Technologies, Inc., H1 2015 75

Colon Cancer-Pipeline by Aphios Corporation, H1 2015 76

Colon Cancer-Pipeline by Apogenix GmbH, H1 2015 77

Colon Cancer-Pipeline by Aposense Ltd., H1 2015 78

Colon Cancer-Pipeline by AstraZeneca Plc, H1 2015 79

Colon Cancer-Pipeline by Aurigene Discovery Technologies Limited, H1 2015 80

Colon Cancer-Pipeline by Bavarian Nordic A/S, H1 2015 81

Colon Cancer-Pipeline by Bio-Path Holdings, Inc., H1 2015 82

Colon Cancer-Pipeline by Bioncotech Therapeutics S.L., H1 2015 83

Colon Cancer-Pipeline by Bionomics Limited, H1 2015 84

Colon Cancer-Pipeline by Carna Biosciences, Inc., H1 2015 85

Colon Cancer-Pipeline by Celyad, H1 2015 86

Colon Cancer-Pipeline by Cold Genesys, Inc., H1 2015 87

Colon Cancer-Pipeline by Critical Outcome Technologies Inc., H1 2015 88

Colon Cancer-Pipeline by CureFAKtor Pharmaceuticals, LLC, H1 2015 89

Colon Cancer-Pipeline by CytomX Therapeutics, Inc., H1 2015 90

Colon Cancer-Pipeline by Cytune Pharma SAS, H1 2015 91

Colon Cancer-Pipeline by CZ BioMed Corp, H1 2015 92

Colon Cancer-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 93

Colon Cancer-Pipeline by DEKK-TEC, Inc., H1 2015 94

Colon Cancer-Pipeline by Digna Biotech, S.L., H1 2015 95

Colon Cancer-Pipeline by EntreChem, S.L., H1 2015 96

Colon Cancer-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 97

Colon Cancer-Pipeline by GlycaNova Norway AS, H1 2015 98

Colon Cancer-Pipeline by Histogen, Inc., H1 2015 99

Colon Cancer-Pipeline by Idera Pharmaceuticals, Inc., H1 2015 100

Colon Cancer-Pipeline by Ignyta, Inc., H1 2015 101

Colon Cancer-Pipeline by Ildong Pharmaceutical Co., Ltd., H1 2015 102

Colon Cancer-Pipeline by ImmunoCellular Therapeutics, Ltd., H1 2015 103

Colon Cancer-Pipeline by Immunomedics, Inc., H1 2015 104

Colon Cancer-Pipeline by Immunotope, Inc., H1 2015 105

Colon Cancer-Pipeline by Innopharmax Inc., H1 2015 106

Colon Cancer-Pipeline by Intezyne, Inc, H1 2015 107

Colon Cancer-Pipeline by Intrexon Corporation, H1 2015 108

Colon Cancer-Pipeline by Ironwood Pharmaceuticals, Inc., H1 2015 109

Colon Cancer-Pipeline by Jasco Pharmaceuticals, LLC., H1 2015 110

Colon Cancer-Pipeline by JW Pharmaceutical Corporation, H1 2015 111

Colon Cancer-Pipeline by Karyopharm Therapeutics, Inc., H1 2015 112

Colon Cancer-Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 113

Colon Cancer-Pipeline by Les Laboratoires Servier SAS, H1 2015 114

Colon Cancer-Pipeline by MabVax Therapeutics Holdings, Inc., H1 2015 115

Colon Cancer-Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 116

Colon Cancer-Pipeline by Molecular Targeting Technologies, Inc., H1 2015 117

Colon Cancer-Pipeline by MolMed S.p.A., H1 2015 118

Colon Cancer-Pipeline by Multimmune GmbH, H1 2015 119

Colon Cancer-Pipeline by Nanobiotix, H1 2015 120

Colon Cancer-Pipeline by Nektar Therapeutics, H1 2015 121

Colon Cancer-Pipeline by Novartis AG, H1 2015 122

Colon Cancer-Pipeline by Omeros Corporation, H1 2015 123

Colon Cancer-Pipeline by Omnitura Therapeutics Inc., H1 2015 124

Colon Cancer-Pipeline by Oncology Research International Limited, H1 2015 125

Colon Cancer-Pipeline by OncoVista Innovative Therapies, Inc., H1 2015 126

Colon Cancer-Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 127

Colon Cancer-Pipeline by Orega Biotech SAS, H1 2015 128

Colon Cancer-Pipeline by OSE Pharma SA, H1 2015 129

Colon Cancer-Pipeline by Panacea Pharmaceuticals, Inc., H1 2015 130

Colon Cancer-Pipeline by Panacela Labs, Inc., H1 2015 131

Colon Cancer-Pipeline by PharmAbcine, Inc., H1 2015 132

Colon Cancer-Pipeline by Pharminox Limited, H1 2015 133

Colon Cancer-Pipeline by Philogen S.p.A., H1 2015 134

Colon Cancer-Pipeline by Pique Therapeutics, H1 2015 135

Colon Cancer-Pipeline by Plexxikon Inc., H1 2015 136

Colon Cancer-Pipeline by Priaxon AG, H1 2015 137

Colon Cancer-Pipeline by Provecs Medical GmbH, H1 2015 138

Colon Cancer-Pipeline by Provectus Biopharmaceuticals, Inc., H1 2015 139

Colon Cancer-Pipeline by Qu Biologics Inc., H1 2015 140

Colon Cancer-Pipeline by Rexahn Pharmaceuticals, Inc., H1 2015 141

Colon Cancer-Pipeline by Sareum Holdings Plc, H1 2015 142

Colon Cancer-Pipeline by Sigma-Tau S.p.A., H1 2015 143

Colon Cancer-Pipeline by Sirnaomics, Inc., H1 2015 144

Colon Cancer-Pipeline by Starpharma Holdings Limited, H1 2015 145

Colon Cancer-Pipeline by Synta Pharmaceuticals Corp., H1 2015 146

Colon Cancer-Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 147

Colon Cancer-Pipeline by Tiziana Life Sciences Plc, H1 2015 148

Colon Cancer-Pipeline by Transgene Biotek Limited, H1 2015 149

Colon Cancer-Pipeline by TVAX Biomedical, Inc., H1 2015 150

Colon Cancer-Pipeline by Tyg Oncology Ltd., H1 2015 151

Colon Cancer-Pipeline by Vaccinogen, Inc., H1 2015 152

Colon Cancer-Pipeline by Viventia Biotechnologies Inc., H1 2015 153

Colon Cancer-Pipeline by vTv Therapeutics Inc., H1 2015 154

Colon Cancer-Pipeline by Yakult Honsha Co., Ltd., H1 2015 155

Colon Cancer-Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H1 2015 156

Assessment by Monotherapy Products, H1 2015 157

Assessment by Combination Products, H1 2015 158

Number of Products by Stage and Target, H1 2015 160

Number of Products by Stage and Mechanism of Action, H1 2015 166

Number of Products by Stage and Route of Administration, H1 2015 171

Number of Products by Stage and Molecule Type, H1 2015 173

Colon Cancer Therapeutics-Recent Pipeline Updates, H1 2015 444

Colon Cancer-Dormant Projects, H1 2015 509

Colon Cancer-Dormant Projects (Contd..1), H1 2015 510

Colon Cancer-Dormant Projects (Contd..2), H1 2015 511

Colon Cancer-Dormant Projects (Contd..3), H1 2015 512

Colon Cancer-Dormant Projects (Contd..4), H1 2015 513

Colon Cancer-Dormant Projects (Contd..5), H1 2015 514

Colon Cancer-Dormant Projects (Contd..6), H1 2015 515

Colon Cancer-Dormant Projects (Contd..7), H1 2015 516

Colon Cancer-Dormant Projects (Contd..8), H1 2015 517

Colon Cancer-Dormant Projects (Contd..9), H1 2015 518

Colon Cancer-Dormant Projects (Contd..10), H1 2015 519

Colon Cancer-Dormant Projects (Contd..11), H1 2015 520

Colon Cancer-Dormant Projects (Contd..12), H1 2015 521

Colon Cancer-Discontinued Products, H1 2015 522

List of Figures

Number of Products under Development for Colon Cancer, H1 2015 31

Number of Products under Development for Colon Cancer-Comparative Analysis, H1 2015 32

Number of Products under Development by Companies, H1 2015 33

Number of Products under Investigation by Universities/Institutes, H1 2015 43

Comparative Analysis by Clinical Stage Development, H1 2015 49

Comparative Analysis by Early Stage Products, H1 2015 50

Assessment by Monotherapy Products, H1 2015 157

Number of Products by Top 10 Targets, H1 2015 159

Number of Products by Stage and Top 10 Targets, H1 2015 159

Number of Products by Top 10 Mechanism of Actions, H1 2015 165

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 165

Number of Products by Top 10 Routes of Administration, H1 2015 170

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 170

Number of Products by Top 10 Molecule Types, H1 2015 172

Number of Products by Stage and Top 10 Molecule Types, H1 2015 172

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Aduro BioTech, Inc.

Advanced Proteome Therapeutics Corporation

Advenchen Laboratories, LLC

AGV Discovery, SAS

AIMM Therapeutics B.V.

Alethia Biotherapeutics Inc.

AlphaVax, Inc.

Ambrx, Inc.

Anavex Life Sciences Corp.

AndroScience Corporation

ANP Technologies, Inc.

Aphios Corporation

Apogenix GmbH

Aposense Ltd.

AstraZeneca Plc

Aurigene Discovery Technologies Limited

Bavarian Nordic A/S

Bio-Path Holdings, Inc.

Bioncotech Therapeutics S.L.

Bionomics Limited

Carna Biosciences, Inc.

Celyad

Cold Genesys, Inc.

Critical Outcome Technologies Inc.

CureFAKtor Pharmaceuticals, LLC

CytomX Therapeutics, Inc.

Cytune Pharma SAS

CZ BioMed Corp

Daiichi Sankyo Company, Limited

DEKK-TEC, Inc.

Digna Biotech, S.L.

EntreChem, S.L.

F. Hoffmann-La Roche Ltd.

GlycaNova Norway AS

Histogen, Inc.

Idera Pharmaceuticals, Inc.

Ignyta, Inc.

Ildong Pharmaceutical Co., Ltd.

ImmunoCellular Therapeutics, Ltd.

Immunomedics, Inc.

Immunotope, Inc.

Innopharmax Inc.

Intezyne, Inc

Intrexon Corporation

Ironwood Pharmaceuticals, Inc.

Jasco Pharmaceuticals, LLC.

JW Pharmaceutical Corporation

Karyopharm Therapeutics, Inc.

Kyowa Hakko Kirin Co., Ltd.

Les Laboratoires Servier SAS

MabVax Therapeutics Holdings, Inc.

Millennium Pharmaceuticals, Inc.

Molecular Targeting Technologies, Inc.

MolMed S.p.A.

Multimmune GmbH

Nanobiotix

Nektar Therapeutics

Novartis AG

Omeros Corporation

Omnitura Therapeutics Inc.

Oncology Research International Limited

OncoVista Innovative Therapies, Inc.

Ono Pharmaceutical Co., Ltd.

Orega Biotech SAS

OSE Pharma SA

Panacea Pharmaceuticals, Inc.

Panacela Labs, Inc.

PharmAbcine, Inc.

Pharminox Limited

Philogen S.p.A.

Pique Therapeutics

Plexxikon Inc.

Priaxon AG

Provecs Medical GmbH

Provectus Biopharmaceuticals, Inc.

Qu Biologics Inc.

Rexahn Pharmaceuticals, Inc.

Sareum Holdings Plc

Sigma-Tau S.p.A.

Sirnaomics, Inc.

Starpharma Holdings Limited

Synta Pharmaceuticals Corp.

Teva Pharmaceutical Industries Limited

Tiziana Life Sciences Plc

Transgene Biotek Limited

TVAX Biomedical, Inc.

Tyg Oncology Ltd.

Vaccinogen, Inc.

Viventia Biotechnologies Inc.

vTv Therapeutics Inc.

Yakult Honsha Co., Ltd.

Zensun (Shanghai) Sci & Tech Co., Ltd.

Colon Cancer Therapeutic Products under Development, Key Players in Colon Cancer Therapeutics, Colon Cancer Pipeline Overview, Colon Cancer Pipeline, Colon Cancer Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com